Please Wait
Applying Filters...
menu
    • menu
    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Ecnoglutide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sciwind to Highlight Positive Results for Ecnoglutide and Amylin Analogs
    Sciwind to Highlight Positive Results for Ecnoglutide and Amylin Analogs

    21 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conference-302178846.html

    PR NEWSWIRE
    21 Jun 2024
    Share Share
    Sciwind Announces Publication of Phase 1 Clinical Trial Results of Ecnoglutide
    Sciwind Announces Publication of Phase 1 Clinical Trial Results of Ecnoglutide

    11 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-publication-of-discovery-preclinical-and-phase-1-clinical-trial-results-of-ecnoglutide-xw003-in-molecular-metabolism-301873994.html

    PR NEWSWIRE
    11 Jul 2023
    Share Share
    Sciwind to Highlight Positive Data for GLP-1 Peptide Agonist Ecnoglutide
    Sciwind to Highlight Positive Data for GLP-1 Peptide Agonist Ecnoglutide

    23 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-clinical-data-for-glp-1-peptide-agonist-ecnoglutide-xw003-at-the-american-diabetes-association-ada-83rd-annual-conference-301858192.html

    PR NEWSWIRE
    23 Jun 2023
    Share Share
    Sciwind Announces Initiation of Patient Dosing in PIII Trials of Ecnoglutide
    Sciwind Announces Initiation of Patient Dosing in PIII Trials of Ecnoglutide

    30 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-initiation-of-patient-dosing-in-phase-3-clinical-trials-of-ecnoglutide-xw003-a-long-acting-glp-1-analog-for-the-treatment-of-type-2-diabetes-in-china-301733145.html

    PR NEWSWIRE
    30 Jan 2023
    Share Share
    Sciwind Announces Positive Results from Ongoing Phase 2b Trial of XW003
    Sciwind Announces Positive Results from Ongoing Phase 2b Trial of XW003

    27 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-interim-results-from-ongoing-phase-2b-clinical-trial-of-xw003-ecnoglutide-in-patients-with-obesity-301660847.html

    PRNEWSWIRE
    27 Oct 2022
    Share Share
    Sciwind Biosciences Reports Positive Interim Results from PIc/IIa Trial of XW003
    Sciwind Biosciences Reports Positive Interim Results from PIc/IIa Trial of XW003

    08 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/sciwind-biosciences-reports-positive-interim-results-from-phase-1c2a-clinical-trial-of-xw003-ecnoglutide-in-overweight-and-obese-adult-volunteers-in-china-301599771.html

    PRNEWSWIRE
    08 Aug 2022
    Share Share